This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Quark Pharmaceuticals, Inc.. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Huseyin Aygun: Innovator in RNA Therapeutics
Introduction
Huseyin Aygun is a prominent inventor based in Frankfurt am Main, Germany. He has made significant contributions to the field of RNA therapeutics, holding 2 patents that focus on innovative methods for treating various diseases. His work is characterized by a commitment to advancing medical science through novel approaches.
Latest Patents
Aygun's latest patents include "Double-stranded RNA directed to CASP2 and methods of use thereof." This invention relates to siRNA compounds that possess unique sequences and structural motifs designed to down-regulate the expression of specific human genes. The patent also covers pharmaceutical compositions that include these compounds along with a pharmaceutically acceptable carrier. Furthermore, Aygun has developed a method for treating and preventing diseases associated with these genes by administering the compound or pharmaceutical composition in a therapeutically effective dose.
Another notable patent is "Tandem siRNAs," which provides novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, and respiratory conditions. This invention is based on the inhibition of two or more target genes, showcasing Aygun's innovative approach to complex medical challenges.
Career Highlights
Huseyin Aygun is currently associated with Quark Pharmaceuticals, Inc., where he continues to push the boundaries of RNA research. His work has been instrumental in developing therapies that target critical genetic pathways, thereby offering new hope for patients suffering from various conditions.
Collaborations
Aygun collaborates with esteemed colleagues, including Elena Feinstein and Rami Skaliter. These partnerships enhance the research environment and foster innovation in the field of RNA therapeutics.
Conclusion
Huseyin Aygun stands out as a key figure in the realm of RNA therapeutics, with his patents reflecting a deep understanding of genetic mechanisms and their implications for treatment. His contributions are paving the way for future advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile